+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

2020 Cancer Diagnostics Market Segmentation Analysis: US, Europe, Japan--Cancer Clinics, Commercial Labs, Hospitals, Physician Offices--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains

  • ID: 4991373
  • Report
  • February 2020
  • Region: United States, Europe
  • 1200 pages
  • VPG Market Research
1 of 2

FEATURED COMPANIES

  • Abbott
  • Bio-Rad
  • Diazyme
  • Guided Therapeutics
  • Panacea Pharmaceuticals
  • Sequenom
  • MORE
The report is available by country, section, market segment, and can be custom-tailored to your specific information needs and budget.

This new report is based on a study of the major business opportunities emerging in the global cancer diagnostics market during the next five years. The report examines trends in the U.S., Europe and Asia; reviews current and emerging assays; analyzes potential applications of new diagnostic technologies; forecasts sales of major tumor markers by country and market segment; profiles leading players and potential market entrants; and identifies specific business opportunities for suppliers.

Rationale

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next five years, the worldwide cancer diagnostics market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

Geographic Coverage

France, Germany, Italy, Japan, Spain, UK, USA

Worldwide Market Overview
  • Five-year test volume and sales projections by country.
  • Comprehensive market segmentation analysis, including review of the market dynamics, structure, size, growth and major suppliers by country.
  • Estimated universe of laboratories performing cancer diagnostic testing by country.
  • Cancer statistics, etiology and recent developments in the U.S., Europe, and Asia.
Business Opportunities and Strategic Recommendations
  • Specific new product development opportunities with potentially significant market appeal during the next five years.
  • Design criteria for new products.
  • Alternative market penetration strategies.
  • Potential market entry barriers and risks.
Over 200 Current and Emerging Cancer Diagnostic Test
  • Oncogenes
  • Biochemical Markers
  • Growth Factors
  • Colony Stimulating Factors
  • Hormones
  • Immunohistochemically Stains
  • Lymphokines
Supplier Shares, Sales and Volume Forecasts
  • Sales and market shares of major cancer diagnostic product suppliers by individual test and country.
  • Five-year test volume and sales forecasts for major tumor markers by country and market segment, including:
  • Hospitals
  • Commercial/Private Laboratories
  • Physician Offices/Group Practices
  • Cancer Clinics
  • Ambulatory Care Centers
Instrumentation Review
  • Analysis of major molecular diagnostic and immunodiagnostic analyzers used for cancer testing, including their operating characteristics, features and selling prices.
Technology Assessment
  • Assessment of latest technologies and their potential applications for cancer diagnostic testing.
  • Review of competing/complementing technologies.
  • Extensive listings of companies, universities and research centers developing new cancer diagnostic tests and detection technologies.
Competitive Strategies
  • Strategic assessments of major suppliers and start-up firms developing innovative cancer diagnostic technologies and products, including their sales, product portfolios, marketing tactics, collaborative arrangements, and new products in R&D.
  • The companies analyzed in the report include:
Contains 1,200 pages and 170 tables
Note: Product cover images may vary from those shown
2 of 2
  • Company Assessments
  • - Abbott

  • Agilent Technologies
  • Applied Gene Technologies
  • Arca Biopharma
  • Beckman Coulter/Danaher
  • Becton Dickinson
  • bioMerieux
  • Bio-Rad
  • CellSearch
  • Cepheid
  • Clinical Genomics
  • Decode Genetics
  • DiaSorin
  • Diazyme
  • Eiken Chemical
  • Elitech Group
  • Enzo Biochem
  • Epigenomics
  • Exact Sciences
  • Fujirebio
  • Guided Therapeutics
  • Hologic
  • Janssen Diagnostics
  • Kyowa Medex
  • Leica Biosystems
  • Myriad Genetics
  • OncoLab
  • Ortho-Clinical Diagnostics
  • Panacea Pharmaceuticals
  • PerkinElmer
  • Polymedco
  • Qiagen
  • Quest Diagnostics
  • Roche
  • Scienion
  • Sequenom
  • Siemens Healthineers
  • Takara Bio
  • Theradiag
  • Thermo Fisher
  • Tosoh
  • Vermillion
  • Wako Pure Chemicals
Note: Product cover images may vary from those shown
Adroll
adroll